R&D

News

Roche removes tenecteplase from phase 3 for stroke

Roche said it has removed its thrombolytic drug tenecteplase from phase 3 for for acute ischaemic stroke, along with several earlier-stage projects.

R&D

Disease X is coming. Are we ready?

Every great disaster movie begins with a scientist being ignored.

News

Janssen celebrates positive results for JNJ-2113 in psoriasi...

Janssen, a Johnson & Johnson company,

R&D

DIA 2023 – a “patients included” global event

The 2023 Drug Information Association global annual meeting was the ideal setting to put our collective heads together and pool

R&D

Veeva R&D and Quality Summit: Delivering next-generation inn...

Veeva Systems held its R&D and Quality Summit in Madrid from 5th to 7th June, once more returned to the Marriot Auditorium & Conference Centre – which only just about held the event

News

Top incentive for joining a clinical trial? The pay

A survey of people in the UK has found that two thirds (69%) of them would consider taking part in a clinical trial, with a financial incentive the most compelling reason

Roche removes tenecteplase from phase 3 for stroke

Disease X is coming. Are we ready?

Janssen celebrates positive results for JNJ-2113 in psoriasi...

DIA 2023 – a “patients included” global event

Veeva R&D and Quality Summit: Delivering next-generation inn...

Top incentive for joining a clinical trial? The pay

ASH: AstraZeneca's dual-wielding CAR-T shows promise

How to meet your physicians where they are online

R&D

Editor's Picks